pH Imaging in Multiple Sclerosis
| Status: | Recruiting |
|---|---|
| Conditions: | Neurology, Neurology, Multiple Sclerosis |
| Therapuetic Areas: | Neurology, Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 10/24/2018 |
| Start Date: | May 1, 2017 |
| End Date: | June 2019 |
| Contact: | Daniella Frew |
| Email: | daniella.frew@nyumc.org |
| Phone: | 212 263 3784 |
pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress
Twenty subjects (10 patients and 10 age-matched control volunteers) will be recruited for
this study. MRI scans will take place on a 3T MRI Scanner (Skyra or Prisma, Siemens Medical
Solutions) located at The NYU Center for Biomedical Imaging. MRI scans will consist of a
1-hour brain scan for both patients and controls. In the first 6 months of the study,
investigators will develop and test a uMT-based APT imaging for brain tissue pH measurement
and use a hypercapnia paradigm to validate the tissue pH changes between breathing room air
and 5% CO2 (by increasing tissue acidity) inhalation. With implementation of hypercapnia MRI,
pH-weighted imaging will be validated for its robustness and reproducibility.
this study. MRI scans will take place on a 3T MRI Scanner (Skyra or Prisma, Siemens Medical
Solutions) located at The NYU Center for Biomedical Imaging. MRI scans will consist of a
1-hour brain scan for both patients and controls. In the first 6 months of the study,
investigators will develop and test a uMT-based APT imaging for brain tissue pH measurement
and use a hypercapnia paradigm to validate the tissue pH changes between breathing room air
and 5% CO2 (by increasing tissue acidity) inhalation. With implementation of hypercapnia MRI,
pH-weighted imaging will be validated for its robustness and reproducibility.
The contrast agent (Gd-DTPA, Gadavist) will be injected intravenously (IV) in the arm
(patients only). The IV will be inserted by qualified medical professional at CBI. This
contrast agent will be standard dose in accordance with its FDA approved labeling and dosing.
Controls will NOT be administered the contrast agent.
(patients only). The IV will be inserted by qualified medical professional at CBI. This
contrast agent will be standard dose in accordance with its FDA approved labeling and dosing.
Controls will NOT be administered the contrast agent.
Inclusion Criteria:
- Healthy male or female non-MS control volunteers
Exclusion Criteria:
- Medically unstable or with cardiac, pulmonary, hematological, renal, or hepatic
dysfunction.
- Current or past DSM-IV diagnosis of major depression, bipolar and psychotic disorders.
- Contraindications for MRI, including
- Intracranial clips
- Metal implants
- External metallic devices/objects/clips within 10mm of the head
- Suspected or confirmed metal in the eyes (history of welding or similar activity)
- Claustrophobia
- Cardiac pacemaker or pacing wires
- Pregnancy - Pregnancy tests will be offered to women of childbearing age at no cost to
the subject
- History of moderate to severe head injury, stroke, and seizures.
- Alcoholism or drug dependency.
- Renal or liver disease as this may cause concerns related to Gd-DTPA contrast agent.
- Allergy to the contrast agent Gadolinium
- Relapses or steroid therapy in patient at or in the month preceding the study
- Patients only
We found this trial at
1
site
550 1st Ave
New York, New York 10016
New York, New York 10016
(212) 263-7300
Principal Investigator: Yulin Ge, MD
New York University School of Medicine NYU School of Medicine has a proud history that...
Click here to add this to my saved trials
